NCT05358756 is a Phase 1 clinical trial of SACT-1 in Healthy Subject, sponsored by Aptorum International Limited.

Who is sponsoring NCT05358756?

NCT05358756 is sponsored by Aptorum International Limited.

What drugs are being tested in NCT05358756?

Interventions in NCT05358756: SACT-1, EDURANT 25Mg Tablet.

What condition does NCT05358756 study?

NCT05358756 studies Healthy Subject.

Is NCT05358756 still recruiting?

NCT05358756 is currently completed. Last updated 26 May 2022.

Last reviewed 2022-05-26 · How we verify

NCT05358756

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers

Completed Phase 1 Last updated 26 May 2022

What this trial tests

Phase 1 trial testing SACT-1 in Healthy Subject in 16 participants. Completed in 14 December 2021.

Timeline

9 October 2021

Primary endpoint
20 November 2021

14 December 2021

Quick facts

Lead sponsor	Aptorum International Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	9 October 2021
Primary completion	20 November 2021
Estimated completion	14 December 2021
Sites	1 location across United States

Drugs / interventions tested

SACT-1 — full drug profile →
EDURANT 25Mg Tablet — full drug profile →

Conditions studied

Healthy Subject — all drugs for Healthy Subject →

Sponsor

Aptorum International Limited — full company profile →

Who can join

18 and older, any sex, with Healthy Subject. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a Phase 1, open-label, randomized, single center, 3-period, 3-sequence, single-dose crossover bioavailability and food effect study between SACT-1 and Edurant® tablet.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Subject

Currently open trials in the same condition.

NCT03897270 — Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects · NA · recruiting
NCT03303846 — Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients · NA · active not recruiting
NCT03491176 — Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer · active not recruiting
NCT03207854 — Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers · recruiting
NCT03199365 — Tu Salud Si Cuenta Intervention in Increasing Physical Activity and Healthy Eating Among Latino Families · NA · active not recruiting

Other Aptorum International Limited trials

Trials by the same sponsor.

NCT05274802 — A Study of ALS-4 in Healthy Adults Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05358756 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aptorum International Limited
Last refreshed: 26 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05358756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing